文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

骨髓移植中的肺损伤预测模型:一项多中心队列研究

Lung Injury Prediction Model in Bone Marrow Transplantation: A Multicenter Cohort Study.
PubMed 文献 · Am J Respir Crit Care Med · 2024-01-01
一句话结论一个22分预测模型整合移植前、移植后及入院早期(<24小时)变量,可可靠预测造血干细胞移植后ARDS及有创/无创通气需求。

该多中心队列研究纳入2019年1月1日至2021年12月31日在三家机构接受造血干细胞移植的患者,Rochester, MN中心患者组成推导队列,Scottsdale, AZ或Jacksonville, FL中心患者组成验证队列。主要结局为急性呼吸窘迫综合征(ARDS)的发生,次要结局为需要有创机械通气(IMV)和/或无创通气(NIV)。推导队列含1,718次住院(888例患者),验证队列含1,005次住院(470例患者),共2,450例接受干细胞移植患者。建立的22分模型(移植前预测因子11分,移植后或入院早期<24小时预测因子11分)在推导队列预测ARDS的C统计量为0.905(95%CI 0.870-0.941),预测IMV和/或NIV需求的C统计量为0.863(95%CI 0.828-0.898);在人口学、医学和血液学特征明显不同的验证队列中,预测ARDS的C统计量为0.841(95%CI 0.782-0.900),预测IMV和/或NIV需求的C统计量为0.872(95%CI 0.831-0.914)。结论认为该新型预测模型可可靠预测HCT后急性呼吸衰竭的发生。

要点

  • 模型共22分,其中移植前预测因子占11分,移植后或入院早期(<24小时)预测因子占11分。
  • 推导队列预测ARDS的C统计量为0.905(95%CI 0.870-0.941),预测IMV和/或NIV需求的C统计量为0.863(95%CI 0.828-0.898)。
  • 验证队列预测ARDS的C统计量为0.841(95%CI 0.782-0.900),预测IMV和/或NIV需求的C统计量为0.872(95%CI 0.831-0.914)。
  • 验证队列在人口学、医学和血液学特征上与推导队列明显不同,模型仍表现良好。
  • 识别高危患者有助于将其纳入临床研究,以更好地理解、预防和治疗移植后呼吸衰竭综合征。

适用人群与场景

  • 2019年1月1日至2021年12月31日在三家机构接受造血干细胞移植(HCT)的患者。
  • 推导队列为在Rochester, MN治疗的患者,验证队列为在Scottsdale, AZ或Jacksonville, FL治疗的患者。

研究设计与关键结果

  • 研究类型为多中心队列研究,共2,450例接受干细胞移植患者;推导队列1,718次住院(888例患者),验证队列1,005次住院(470例患者)。
  • 主要结局为ARDS发生,次要结局为需要有创机械通气(IMV)和/或无创通气(NIV)。
  • 推导队列:22分模型预测ARDS的C统计量0.905(95%CI 0.870-0.941),预测IMV和/或NIV需求的C统计量0.863(95%CI 0.828-0.898)。
  • 验证队列:预测ARDS的C统计量0.841(95%CI 0.782-0.900),预测IMV和/或NIV需求的C统计量0.872(95%CI 0.831-0.914)。
  • 验证队列在人口学、医学和血液学特征上与推导队列明显不同。

证据类型、等级与局限

  • 证据类型:多中心队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,该模型可可靠预测HCT后急性呼吸衰竭的发生;识别高危患者有助于将其纳入临床研究,以更好地理解、预防和治疗移植后呼吸衰竭综合征。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Rationale: Pulmonary complications contribute significantly to nonrelapse mortality following hematopoietic stem cell transplantation (HCT). Identifying patients at high risk can help enroll such patients into clinical studies to better understand, prevent, and treat posttransplantation respiratory failure syndromes. Objectives: To develop and validate a prediction model to identify those at increased risk of acute respiratory failure after HCT. Methods: Patients underwent HCT between January 1, 2019, and December 31, 2021, at one of three institutions. Those treated in Rochester, MN, formed the derivation cohort, and those treated in Scottsdale, AZ, or Jacksonville, FL, formed the validation cohort. The primary outcome was the development of acute respiratory distress syndrome (ARDS), with secondary outcomes including the need for invasive mechanical ventilation (IMV) and/or noninvasive ventilation (NIV). Predictors were based on prior case-control studies. Measurements and Main Results: Of 2,450 patients undergoing stem cell transplantation, there were 1,718 hospitalizations (888 patients) in the training cohort and 1,005 hospitalizations (470 patients) in the test cohort. A 22-point model was developed, with 11 points from prehospital predictors and 11 points from posttransplantation or early (<24-h) in-hospital predictors. The model performed well in predicting ARDS (C-statistic, 0.905; 95% confidence interval [CI], 0.870-0.941) and the need for IMV and/or NIV (C-statistic, 0.863; 95% CI, 0.828-0.898). The test cohort differed markedly in demographic, medical, and hematologic characteristics. The model also performed well in this setting in predicting ARDS (C-statistic, 0.841; 95% CI, 0.782-0.900) and the need for IMV and/or NIV (C-statistic, 0.872; 95% CI, 0.831-0.914). Conclusions: A novel prediction model incorporating data elements from the pretransplantation, posttransplantation, and early in-hospital domains can reliably predict the development of post-HCT acute respiratory failure.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Herasevich S, Schulte PJ, Hogan WJ, et al. Lung Injury Prediction Model in Bone Marrow Transplantation: A Multicenter Cohort Study. Am J Respir Crit Care Med. 2024. PMID: 38051944. doi:10.1164/rccm.202308-1524OC

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。